Ketamine

Generic Name
Ketamine
Brand Names
Ketalar
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
6740-88-1
Unique Ingredient Identifier
690G0D6V8H
Background

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic eff...

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior oth...

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia
Clinical Trials
Related News

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

Phase 2
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Drug: Ketamine
Drug: Psilocybin
First Posted Date
2022-06-16
Last Posted Date
2024-03-26
Lead Sponsor
Peggy C Nopoulos
Target Recruit Count
20
Registration Number
NCT05421065
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Phase 2
Not yet recruiting
Conditions
Demoralization
Interventions
Drug: Psilocybin
Drug: Ketamine
First Posted Date
2022-06-03
Last Posted Date
2024-10-09
Lead Sponsor
Charles S. Grob, M.D.
Target Recruit Count
100
Registration Number
NCT05403086

Glutamatergic Mechanisms: Aim2

Phase 1
Suspended
Conditions
Healthy
Interventions
Drug: Ketamine
Drug: Ts-134
Drug: Placebo
First Posted Date
2022-06-02
Last Posted Date
2024-08-14
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
120
Registration Number
NCT05401227
Locations
🇺🇸

NYSPI, New York, New York, United States

Ketamine for Multiple Sclerosis Fatigue

Phase 2
Recruiting
Conditions
Multiple Sclerosis Fatigue
Interventions
Drug: Ketamine
Drug: Midazolam
First Posted Date
2022-05-18
Last Posted Date
2024-01-12
Lead Sponsor
Johns Hopkins University
Target Recruit Count
110
Registration Number
NCT05378100
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Ketamine Pilot Study

Phase 4
Terminated
Conditions
Rattlesnake Envenomation
Interventions
Drug: Ketamine
Drug: Fentanyl
First Posted Date
2022-05-18
Last Posted Date
2024-02-14
Lead Sponsor
Meghan Spyres
Target Recruit Count
3
Registration Number
NCT05379179
Locations
🇺🇸

Banner - University Medical Center, Phoenix campus, Phoenix, Arizona, United States

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Early Phase 1
Recruiting
Conditions
Major Depressive Disorder
Interventions
Other: Placebo
Drug: Ketamine
First Posted Date
2022-04-14
Last Posted Date
2024-07-03
Lead Sponsor
Emory University
Target Recruit Count
140
Registration Number
NCT05327699
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers

First Posted Date
2022-04-11
Last Posted Date
2022-04-18
Lead Sponsor
University Hospital, Bonn
Target Recruit Count
70
Registration Number
NCT05320991
Locations
🇩🇪

Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany

The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects

Phase 1
Recruiting
Conditions
Major Depressive Disorder
Interventions
Drug: Ketamine
Drug: Placebo
First Posted Date
2022-04-11
Last Posted Date
2024-04-15
Lead Sponsor
Medical University of Vienna
Target Recruit Count
60
Registration Number
NCT05320107
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Comparsion of IV Dexmedetomidine, Tramdol and Ketamine for Post Spinal Anesthesia Shivering.

First Posted Date
2022-04-05
Last Posted Date
2022-04-05
Lead Sponsor
Sheikh Zayed Medical College
Target Recruit Count
71
Registration Number
NCT05311722

Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

Phase 3
Recruiting
Conditions
Chronic Daily Headache
Interventions
Other: 0.9% Saline
Drug: Ketamine
First Posted Date
2022-04-01
Last Posted Date
2022-10-18
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
56
Registration Number
NCT05306899
Locations
🇨🇦

Women's College Hospital, Toronto, Ontario, Canada

🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy